首页> 外文期刊>Diabetes management. >Comorbidities and complications: when, how and who to screen and when to treat? Microalbuminuria in adolescents with Type 1 diabetes
【24h】

Comorbidities and complications: when, how and who to screen and when to treat? Microalbuminuria in adolescents with Type 1 diabetes

机译:合并症和并发症:何时,如何以及何时筛查以及何时治疗? 1型糖尿病青少年的微量白蛋白尿

获取原文
获取原文并翻译 | 示例
           

摘要

SUMMARY Progressive increases in albumin excretion and microalbuminuria can be detected in young people with childhood-onset Type 1 diabetes during puberty. Risk factors for microalbuminuria during puberty include hyperglycemia, diabetes duration, female gender, high blood pressure and lipid levels, changes in sex hormones, reduced IGF-I levels, together with other, as yet unidentified, genetic and environmental factors. Annual screening for microalbuminuria during puberty is recommended for the early detection of this marker of later diabetes complications. When microalbuminuria is detected, the first treatment strategy is to improve glycemic control, a known modifiable risk factor, whereas the efficacy and safety of additional interventions, such as angiotensin-converting enzyme inhibitors or statins, is not yet established, and are currently being evaluated.
机译:发明内容在青春期期间,在患有儿童期1型糖尿病的年轻人中可以检测到白蛋白排泄和微量白蛋白的逐渐增加。青春期微量白蛋白尿的危险因素包括高血糖,糖尿病持续时间,女性,高血压和血脂水平,性激素变化,IGF-I水平降低,以及其他尚未确定的遗传和环境因素。建议在青春期期间每年对微量白蛋白尿进行筛查,以早期发现这种糖尿病后期并发症的标志物。当检测到微量白蛋白尿时,第一种治疗策略是改善血糖控制,这是一种已知的可改变的危险因素,而诸如血管紧张素转化酶抑制剂或他汀类药物等其他干预措施的功效和安全性尚未建立,目前正在评估中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号